QLI: qlsyy.net EV/EBITDA Multiple
The price trend visualization on the GURU.Markets platform shows that Qilian International (QLI) has an EV/EBITDA of . Current business revenue is based on the sale of basic chemical components and traditional medicine products. A high barrier to entry is ensured by government licensing and strict control over raw material flows. The company's stability relies on its own plants in China and steady domestic demand.
Analytical breakdowns and data insights for company qlsyy.net (QLI)
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- debt and solvency information:
Debt to Equity Qilian International|QLI - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Qilian International Holding|QLI - Company Total Debt Obligations|Debt to Book Capitalization Ratio Qilian International Corp|QLI - Company Long-Term Debt|Company Short-Term Debts Qilian International|Quick Ratio qlsyy.net
- financial results and valuation multiples details:
QLI - Net Profit|Expected Profit Qilian International|QLI - Price to Earnings Multiple|Projected Price to Earnings Qilian International|QLI - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Qilian International Corp|QLI - Operating income before deduction of amortization|Earnings per share for the last twelve months Qilian International|QLI - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months qlsyy.net|QLI - Net earnings per one share growth for the current year|Earnings growth forecast for next year Qilian International
Comprehensive company analysis:QLI (Qilian International Holding Group Limited)
Stable demand for chemical raw materials at Qilian International (QLI) creates a predictable cash flow, which serves as the basis for calculating business value adjusted for net debt. By analyzing the current EV/EBITDA multiple, an investor compares market capitalization with operating profit before interest, taxes, depreciation, and amortization. Low levels on this chart confirm a fundamental undervaluation of assets, while sharp peaks signal that the securities are overbought.
Who Qilian International competes with
Haleon Group - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KVUE (Kenvue Health)|Verona Pharma plc - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation MENS (jyongbio.com)|LGND: EV/EBITDA Multiple|Company Value to EBITDA Amneal Pharmaceuticals, Inc. (AMRX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Perrigo Company|ALVO: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|glpg.com (GLPG) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio MannKind Corp (MNKD)|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SPRY: EV/EBITDA Multiple|TBPH - Total Company Value to Operating Income Before Depreciation Ratio|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple scPharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Tonix Pharmaceuticals Holding - Enterprise Value to Operating Income Before Depreciation|China SXT Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation EPRX|BioHarvest Sciences Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Invizyne Technologies EXOZ|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ENTX|Enterprise Value to EBITDA Ratio HYFT|ABVC (abvcpharma.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CPIX|QNTM - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen Corp FGEN|Business Value to Operating Income Before Depreciation TELO|RANI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNYR (Synergy CHC Corp) - Enterprise Value to Operating Income Before Depreciation|RLYB: EV/EBITDA Multiple|Lexaria Bioscience Corp. (LEXX) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PULM|PTHL (Pheton) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APM|Total Company Value to Operating Income Before Depreciation Ratio lyratherapeutics.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Impact BioMedical IBO|TNF Pharmaceuticals Inc. (TNFA) - Company Value to EBITDA|YCBD - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRFX (PainReform Corp) - Enterprise Value to Operating Income Before Depreciation|CYTO: EV/EBITDA Multiple|lipella.com (LIPO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OptiNose|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PIRS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Procaps Group SA (PROC)|Petros Pharma (PTPI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|tffpharma.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
